AIMS: Cardiovascular disease (CVD) remains the leading cause of death worldwide despite improvements in the treatment of atherosclerosis, an inflammatory disease and major underlying cause of CVD. Monocytes, an innate immune cell type, are linked to CVD progression; however, given their heterogeneity, the association between distinct monocyte subsets and increased risk of CVD remains unclear. This study investigated the association between peripheral monocyte subpopulation numbers and carotid intima-media thickness (cIMT), a sensitive measure of CVD risk, in a cohort of adults recruited from the general population. METHODS: We used clinical data and peripheral blood mononuclear cell (PBMC) specimens from 67 individuals. cIMT was measured by high-resolution, B-mode, ultrasound images of the right carotid artery. PBMCs were stained with conjugated monoclonal antibodies to define monocyte subpopulations based on CD14 and CD16 co-expressions into classical (CD14＋＋CD16－), intermediate/inflammatory (CD14＋＋CD16＋), and non-classical/patrolling (CD14low/＋CD16＋＋) monocytes. RESULTS: We found a higher intermediate monocyte count was significantly correlated with increased right common carotid artery (RCCA) and right carotid bifurcation (RBIF) intima-media thickness (IMT) (p=0.004 and 0.006,respectively), even after adjusting for CVD-associated clinical data (p=0.006 and 0.004, respectively). CONCLUSION: Our study demonstrated a strong correlation between inflammatory monocyte counts and cIMT. These results suggest that, in the general population, there is a relationship between intermediate monocyte expansion and elevated predictors for CVD risk, and intermediate monocytes may be involved in the development of atherosclerosis and metabolic diseases. Strategies targeting inflammatory monocytes may be needed to slow CVD progression.
AIMS: Cardiovascular disease (CVD) remains the leading cause of death worldwide despite improvements in the treatment of atherosclerosis, an inflammatory disease and major underlying cause of CVD. Monocytes, an innate immune cell type, are linked to CVD progression; however, given their heterogeneity, the association between distinct monocyte subsets and increased risk of CVD remains unclear. This study investigated the association between peripheral monocyte subpopulation numbers and carotid intima-media thickness (cIMT), a sensitive measure of CVD risk, in a cohort of adults recruited from the general population. METHODS: We used clinical data and peripheral blood mononuclear cell (PBMC) specimens from 67 individuals. cIMT was measured by high-resolution, B-mode, ultrasound images of the right carotid artery. PBMCs were stained with conjugated monoclonal antibodies to define monocyte subpopulations based on CD14 and CD16 co-expressions into classical (CD14＋＋CD16－), intermediate/inflammatory (CD14＋＋CD16＋), and non-classical/patrolling (CD14low/＋CD16＋＋) monocytes. RESULTS: We found a higher intermediate monocyte count was significantly correlated with increased right common carotid artery (RCCA) and right carotid bifurcation (RBIF) intima-media thickness (IMT) (p=0.004 and 0.006,respectively), even after adjusting for CVD-associated clinical data (p=0.006 and 0.004, respectively). CONCLUSION: Our study demonstrated a strong correlation between inflammatory monocyte counts and cIMT. These results suggest that, in the general population, there is a relationship between intermediate monocyte expansion and elevated predictors for CVD risk, and intermediate monocytes may be involved in the development of atherosclerosis and metabolic diseases. Strategies targeting inflammatory monocytes may be needed to slow CVD progression.
Authors: Eanna P Connaughton; Serika Naicker; Shirley A Hanley; Stephanie M Slevin; John K Eykelenboom; Noel F Lowndes; Timothy O'Brien; Rhodri Ceredig; Matthew D Griffin; Michael C Dennedy Journal: Immunol Cell Biol Date: 2018-03-05 Impact factor: 5.126
Authors: Gunnar H Heine; Alberto Ortiz; Ziad A Massy; Bengt Lindholm; Andrzej Wiecek; Alberto Martínez-Castelao; Adrian Covic; David Goldsmith; Gültekin Süleymanlar; Gérard M London; Gianfranco Parati; Rosa Sicari; Carmine Zoccali; Danilo Fliser Journal: Nat Rev Nephrol Date: 2012-03-13 Impact factor: 28.314
Authors: A S Justo-Junior; L M Villarejos; X T V Lima; W Nadruz; A C Sposito; R L Mamoni; R Abdalla; J L Fernandes; R T D Oliveira; M H S L Blotta Journal: Cytokine Date: 2018-06-20 Impact factor: 3.861
Authors: Victoria Stoneman; Denise Braganza; Nichola Figg; John Mercer; Richard Lang; Martin Goddard; Martin Bennett Journal: Circ Res Date: 2007-02-22 Impact factor: 17.367
Authors: Cecilia M Shikuma; Dominic C Chow; Louie Mar A Gangcuangco; Guangxiang Zhang; Sheila M Keating; Philip J Norris; Todd B Seto; Nisha Parikh; Kalpana J Kallianpur; Beau K Nakamoto; Lorna S Nagamine; Lishomwa C Ndhlovu; Jason D Barbour Journal: PLoS One Date: 2014-02-27 Impact factor: 3.240
Authors: Camille Lassale; Alyscia Curtis; Itziar Abete; Yvonne T van der Schouw; W M Monique Verschuren; Yunxia Lu; H B As Bueno-de-Mesquita Journal: Sci Rep Date: 2018-02-19 Impact factor: 4.379
Authors: Abhineet M Sharma; Robert Birkett; Erika T Lin; Linda M Ernst; William A Grobman; Suchitra Swaminathan; Hiam Abdala-Valencia; Alexander V Misharin; Elizabeth T Bartom; Karen K Mestan Journal: JCI Insight Date: 2022-06-08
Authors: M Reijrink; J van Ark; C P H Lexis; L M Visser; M E Lodewijk; I C C van der Horst; C J Zeebregts; H van Goor; S C A de Jager; G Pasterkamp; B H R Wolffenbuttel; J L Hillebrands Journal: Cardiovasc Diabetol Date: 2022-05-12 Impact factor: 8.949
Authors: Lishomwa C Ndhlovu; Philip J Norris; Erika G Marques de Menezes; Xutao Deng; Jocelyn Liu; Scott A Bowler; Cecilia M Shikuma; Mars Stone; Peter W Hunt Journal: mBio Date: 2022-04-18 Impact factor: 7.786
Authors: Amber B Ouweneel; Myrthe E Reiche; Olga S C Snip; Robbert Wever; Ezra J van der Wel; Frank H Schaftenaar; Soňa Kauerova; Esther Lutgens; Miranda Van Eck; Menno Hoekstra Journal: J Cell Sci Date: 2021-11-16 Impact factor: 5.285